ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMDespesas comerciais, gerais e administrativas244.33 M253.88 M248.53 M241.91 M251.73 M996.05 MPesquisa e desenvolvimento49.21 M57.89 M53.27 M50.8 M58.18 M220.13 MLucro operacional118.75 M75.89 M90.76 M81.9 M111.75 M360.29 MLucro não operacional, total-24.19 M-25.89 M-22.11 M-26.21 M-20.19 M-94.4 MDespesa com juros, líquida de juros capitalizados22.78 M24.72 M22.94 M22.77 M23.51 M93.94 MReceitas não operacionais, líquidas das despesas com juros-24.19 M-50.61 M-45.05 M-44.95 M-43.7 M-184.31 MReceitas/despesas incomuns———-4.03 M——Lucro antes dos impostos94.56 M49.99 M68.65 M55.69 M91.56 M265.89 MParticipação no lucro——————Impostos6.17 M9.1 M13.43 M8.46 M-4.21 M26.78 MParticipação de minoritários——————Outras receitas/despesas após impostos——————Lucro líquido antes das operações descontinuadas88.38 M40.89 M55.22 M47.22 M95.77 M239.11 MOperações descontinuadas6.26 M-175 K-1.27 M-569 K2.59 M575 KLucro líquido94.64 M40.72 M53.95 M46.65 M98.36 M239.68 MAjuste de diluição——————Dividendos de ações preferenciais——————Lucro líquido diluído disponível aos acionistas94.64 M40.72 M53.95 M46.65 M98.36 M239.68 MLucro básico por ação0.780.360.460.40.862.08Lucro diluído por ação0.770.360.460.40.862.08Número médio de ações básicas122.76 M111.85 M117.51 M115.41 M116.54 M—Ações diluídas122.82 M111.88 M117.54 M115.46 M116.59 M—EBITDA163.97 M90.77 M108.24 M99.86 M229.63 M528.49 MEBIT58.93 M-14.29 M5.46 M-2.2 M126.55 M115.51 MCusto da receita—323.46 M327.73 M324.35 M——Outros componentes do custo——————Amortização e depreciação (fluxo de caixa)105.03 M105.06 M102.78 M102.06 M103.08 M412.97 M
Revvity, Inc. Common Stock
Revvity, Inc. is an American company in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments. Its origins lie with the long-existing company PerkinElmer, which has been in a variety of business lines.
In 2022, a split of PerkinElmer resulted in one part, comprising its applied, food and enterprise services businesses, being sold to the private equity firm New Mountain Capital for $2.45 billion and thus no longer being public but keeping the PerkinElmer name. The other part, comprising the life sciences and diagnostics businesses, remained public but required a new name, which in 2023 was announced as Revvity, Inc. From the perspective of Revvity, the goal of creating a separate company was that its businesses might show greater profit margins and more in the way of growth potential. An associated goal was to have more financial flexibility moving forward. On May 16, 2023, the PerkinElmer stock symbol PKI was replaced by the new symbol RVTY.